News

The new study was published in the current edition of Clinical Cancer Research, a journal of the American Association for cancer research. Seliciclib is currently in Phase 2

Medical device product sales decreased $1.3m to $2.7m and laboratory and scientific product sales decreased $200,000 to $654,000 for the three months ended December 31, 2009. Gross profit

Total revenue was $61.7m, up 84% from $33.5m on the comparable period last year. Revenue included $56.7m of Relenza royalties $1.4m of collaboration income from licensing agreements with

BG Medicine is expected to pursue development and validation of an immunoassay and investigate its clinical utility as a biomarker. If successful, BG Medicine plans to complete the

In the new study of treatment-experienced HIV-1-infected adults with no Prezista resistance-associated mutations (RAMs), 72% of patients in the Prezista/ritonavir (800/100 mg) once-daily arm achieved undetectable viral loads

The issued Hong Kong patent, HK 1071054, entitled ‘Stabilized Reverse Micelle Compositions and Uses Thereof’ covers lipid structures that promote the intestinal absorption of peptides and other sensitive

The lot-to-lot consistency trial will enroll approximately 2,000 patients in Canada and in the US, 1600 of whom will receive Heplisav, an investigational adult hepatitis B vaccine. Patients

The decrease in revenue was impacted by the relocation of the LRT manufacturing facility in the summer of 2009. The consolidation of the LRT facility necessitated GMP re-certification

Collaboration between the two organizations will ensure the sanitary and epidemiological well being of the country’s inhabitants during scientific research, development work, production, consumption, and disposal of products,